WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
* The 12th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing the power and versatile applications of WuXiBody™ in multiple therapeutic areas SHANGHAI and BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global o...
WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392
SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner OncoImmune on the U.S. Food and Drug ...
WuXi Biologics Receives "Special Award to Investors in Ireland" from Asia Matters
DUBLIN, Dec. 23, 2019 /PRNewswire/ -- December 23, 2019 – WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the "Special Awa...
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
DUNDALK, Ireland, Nov. 23, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in ...
WuXi Biologics Reports Outstanding Interim Results
* 52.4% Year-on-Year Revenue Growth to RMB1,607.1 Million * Net Profit Increased 80.1% Year-on-Year to RMB449.5 Million * Gross Profit Margin, Net Profit Margin and Adjusted Net Profit Margin All Record High * Total Backlog Surged to US$4.6 Billion * 32 New Integrated Projects Including 1...
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
WUXI, China, June 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to expand the new state-of-the-art ...
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract
SHANGHAI, May 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has entered into a strategic partnership L...
WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu
CHENGDU, China, May 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the construction of a new 1.3 million sq. ft....
WuXi Biologics Successfully Completed First FDA Routine GMP Inspection
SHANGHAI, April 17, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that its Drug Substance (DS) and Drug Product (D...
WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
SHANGHAI, April 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclus...
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership
SHANGHAI and BASEL, Switzerland, April 9, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and NBE-Therapeutics (NBE), a privately ow...
WuXi Biologics Wins 2019 CMO Leadership Awards in All Six Core Categories
SHANGHAI and NEW YORK, April 3, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the 2019 CMO Leadersh...
WuXi Biologics Receives "Asia's Best CMO of 2018" Award from IMAPAC
SHANGHAI and SINGAPORE, March 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock Code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the "As...
WuXi Biologics Receives EMA GMP Certificates
SHANGHAI and WUXI, China, March 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received EMA GMP certifica...
WuXi Biologics Continues to Deliver Record Results
HONG KONG, March 18, 2019 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announces its aud...
WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA
- The second product successfully receiving Breakthrough Therapy Designation that WuXi Biologics has enabled its partner to develop SHANGHAI, Feb. 28, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock code: 2269.HK), a leading global open-access biologics technology platform company offe...
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
SHANGHAI and SEOUL, Feb. 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation ("ABL Bio") (298380.KS), a Sout...
EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo (TM) at WuXi Biologics
SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the European Medicines Agency (EMA) has comp...
EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics
SHANGHAI, Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the European Medicines Agency (EMA)has compl...
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership
SHANGHAI and CRANBURY, N.J., Feb. 12, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Amicus Therapeutics ("Amicus") (Nasdaq: F...
